Progressive Supranuclear Palsy (Tauros) . Safety, Tolerability, and Efficacy of Two Different Oral Doses of Zentylor Versus Placebo .

NP-12 // NP031112 // Zentylor // Tideglusib .

This study is ongoing, but not recruiting participants.
First Received: January 13, 2010 Last Updated: October 7, 2010

Brief title Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy


The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy


Enrollment: 146
Study Start Date: December 2009
Estimated Study Completion Date: November 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)

Administrative Data
Organization name Noscira SA
Organization study ID NP031112-08B02
Sponsor Noscira SA
Collaborator i3 Research
Health Authority United States: Food and Drug Administration
Health Authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Health Authority Spain: Spanish Agency of Medicines
Health Authority Germany: Federal Institute for Drugs and Medical Devices

...

ESMO . Erlotinib resultó más efectivo que otros utilizados en la terapia tradicional y mejoró las probabilidades de supervivencia de pacientes con ...

... cáncer de pulmón con mutaciones que activan el gen EGFR, divulgaron hoy científicos.

...

ESMO . El mesilato de eribulina de Eisai mantiene los beneficios en pacientes con cáncer de mama metastásico .

ESMO . Novocure presenta datos sobre el tiempo de vida de la terapia TTF con la quimioterapia .

ESMO . Josep Carreras ofrece un recital benéfico en La Scala para luchar contra el cáncer .